Literature DB >> 15713620

Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.

Saskia M Brachmann1, Kohjiro Ueki, Jeffrey A Engelman, Ronald C Kahn, Lewis C Cantley.   

Abstract

Studies ex vivo have shown that phosphoinositide 3-kinase (PI3K) activity is necessary but not sufficient for insulin-stimulated glucose uptake. Unexpectedly, mice lacking either of the PI3K regulatory subunits p85alpha or p85beta exhibit increased insulin sensitivity. The insulin hypersensitivity is particularly unexpected in p85alpha-/- p55alpha-/- p50alpha-/- mice, where a decrease in p110alpha and p110beta catalytic subunits was observed in insulin-sensitive tissues. These results raised the possibility that decreasing total PI3K available for stimulation by insulin might circumvent negative feedback loops that ultimately shut off insulin-dependent glucose uptake in vivo. Here we present results arguing against this explanation. We show that p110alpha+/- p110beta+/- mice exhibit mild glucose intolerance and hyperinsulinemia in the fasted state. Unexpectedly, p110alpha+/- p110beta+/- mice showed a approximately 50% decrease in p85 expression in liver and muscle. Consistent with this in vivo observation, knockdown of p110 by RNA interference in mammalian cells resulted in loss of p85 proteins due to decreased protein stability. We propose that insulin sensitivity is regulated by a delicate balance between p85 and p110 subunits and that p85 subunits mediate a negative role in insulin signaling independent of their role as mediators of PI3K activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713620      PMCID: PMC549361          DOI: 10.1128/MCB.25.5.1596-1607.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  Insulin stimulates PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins.

Authors:  Y F Liu; K Paz; A Herschkovitz; A Alt; T Tennenbaum; S R Sampson; M Ohba; T Kuroki; D LeRoith; Y Zick
Journal:  J Biol Chem       Date:  2001-01-29       Impact factor: 5.157

2.  Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit.

Authors:  K Ueki; P Algenstaedt; F Mauvais-Jarvis; C R Kahn
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Insulin resistance: a phosphorylation-based uncoupling of insulin signaling.

Authors:  Y Zick
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

4.  Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes.

Authors:  Franck Mauvais-Jarvis; Kohjiro Ueki; David A Fruman; Michael F Hirshman; Kei Sakamoto; Laurie J Goodyear; Matteo Iannacone; Domenico Accili; Lewis C Cantley; C Ronald Kahn
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

5.  The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).

Authors:  V Aguirre; T Uchida; L Yenush; R Davis; M F White
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

6.  Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha.

Authors:  D A Fruman; F Mauvais-Jarvis; D A Pollard; C M Yballe; D Brazil; R T Bronson; C R Kahn; L C Cantley
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta).

Authors:  H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum
Journal:  Science       Date:  2001-06-01       Impact factor: 47.728

8.  A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Authors:  O N Ozes; H Akca; L D Mayo; J A Gustin; T Maehama; J E Dixon; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

9.  Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action.

Authors:  Vincent Aguirre; Eric D Werner; Jodel Giraud; Yong Hee Lee; Steve E Shoelson; Morris F White
Journal:  J Biol Chem       Date:  2001-10-17       Impact factor: 5.157

Review 10.  Phosphoinositide kinases.

Authors:  D A Fruman; R E Meyers; L C Cantley
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  76 in total

1.  A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response.

Authors:  Jonathon N Winnay; Jeremie Boucher; Marcelo A Mori; Kohjiro Ueki; C Ronald Kahn
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

Review 2.  Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes.

Authors:  Prasenjit Manna; Sushil K Jain
Journal:  Cell Physiol Biochem       Date:  2015-02-11

3.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Authors:  Ana Bosch; Zhiqiang Li; Anna Bergamaschi; Haley Ellis; Eneda Toska; Aleix Prat; Jessica J Tao; Daniel E Spratt; Nerissa T Viola-Villegas; Pau Castel; Gerard Minuesa; Natasha Morse; Jordi Rodón; Yasir Ibrahim; Javier Cortes; Jose Perez-Garcia; Patricia Galvan; Judit Grueso; Marta Guzman; John A Katzenellenbogen; Michael Kharas; Jason S Lewis; Maura Dickler; Violeta Serra; Neal Rosen; Sarat Chandarlapaty; Maurizio Scaltriti; José Baselga
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 4.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

5.  PI3K/mTOR signaling regulates prostatic branching morphogenesis.

Authors:  Susmita Ghosh; Hiu Lau; Brian W Simons; Jonathan D Powell; David J Meyers; Angelo M De Marzo; David M Berman; Tamara L Lotan
Journal:  Dev Biol       Date:  2011-10-08       Impact factor: 3.582

6.  PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction.

Authors:  David Garcia-Galiano; Beatriz C Borges; Jose Donato; Susan J Allen; Nicole Bellefontaine; Mengjie Wang; Jean J Zhao; Kenneth M Kozloff; Jennifer W Hill; Carol F Elias
Journal:  JCI Insight       Date:  2017-12-07

Review 7.  Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.

Authors:  Shaodong Guo
Journal:  J Endocrinol       Date:  2014-01-08       Impact factor: 4.286

Review 8.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

Review 10.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.